Keywords: nicox, provides, details, ph, iii, naproxcinod, trials

NicOx provides details of Ph III naproxcinod trials

Article | 18 September 2006

Print This

French drugmaker NicOx SA has announced the details of its proposed Phase III trial program, designed to assess naproxcinod (HCT 3012) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in